Press Releases April 5, 2026 08:00 PM

The Oncology Institute Names Minh Merchant Chief Legal Officer

The Oncology Institute appoints Minh Merchant as Chief Legal Officer to support continued growth and regulatory compliance

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
TOI

The Oncology Institute, a publicly traded oncology care provider, announced the hiring of Minh Merchant as Chief Legal Officer. Merchant brings over 20 years of healthcare legal expertise to oversee the company's legal, regulatory, compliance, and privacy functions, supporting its expansion as a leading value-based oncology group serving approximately 1.9 million patients across 100+ locations in five states.

The Oncology Institute Names Minh Merchant Chief Legal Officer
TOI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Minh Merchant appointed as Chief Legal Officer, bringing extensive healthcare legal experience.
  • TOI continues to scale its operations, emphasizing regulatory compliance and privacy oversight.
  • The company provides value-based, community oncology care to nearly 1.9 million patients with over 180 clinicians across five states.

CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors.

Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law.

“We are excited to welcome Minh to TOI as our Chief Legal Officer,” said Daniel Virnich, MD, CEO of The Oncology Institute. “As our footprint and care model continue to grow, she brings the depth of experience to help TOI continue operate as a compliant and secure national oncology platform.”

“I’m thrilled at the opportunity to join TOI at this important juncture in the organization’s growth as a public company,” commented Ms. Merchant. “The organization’s mission to provide better access and affordability to cancer care is inspiring and I feel that I’m well positioned to help TOI continue its successful navigation of the rapidly evolving healthcare legal and regulatory environment.”

About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
[email protected]

Investors
ICR Healthcare
[email protected]


Risks

  • Regulatory and compliance challenges inherent in the evolving healthcare legal environment could impact operations.
  • Scaling rapidly in multiple states may present integration and operational management risks.
  • Dependence on maintaining payer and regulatory trust to sustain growth and mission effectiveness could be vulnerable to policy changes.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026